Eli Lilly and Co. - LLY Net earnings per share (EPS TTM)

Eli Lilly and Company (LLY) relies on a robust patent portfolio and cutting-edge developments in obesity therapy. Rolling trailing twelve-month net income per share demonstrates the effectiveness of this approach, where 30.49 reflects the metric's baseline. EPS growth is supported by an aggressive expansion of the research staff and steady demand for blockbusters, guaranteeing a multi-year cash flow.
Analytical breakdowns for Eli Lilly and Company

Eli Lilly and Company (LLY) generates monopoly profits from innovations in endocrinology and oncology that translate directly into earnings per share growth, reflecting the effective capitalization of R&D investments. This ratio measures the net residual funds available to shareholders for the year; therefore, the current trailing 12-month EPS serves as an objective indicator of financial stability and the limits of current capital growth.